A Powerful Demonstration: MTM May Be Counterpoint To Pricing Complaints
This article was originally published in RPM Report
A proposed “enhanced” model for Medication Therapy Management in Medicare Part D draws rave reviews from a House subcommittee. The prospect of using medication better to lower overall costs is a great counterpoint to headlines about excessive drug prices.
You may also be interested in...
US Centers for Medicare and Medicaid Services announces first-year results from its medication therapy management model, intended to optimize prescription drug use among Medicare beneficiaries.
Medicare drug plans and retail pharmacy groups are working together to clean up the mess that plagued the launch of Part D. The manufacturers should pay attention: the result may be new force in drug selection and adherence.
Biopharma companies are understandably upset by the Biden Administration’s decision to support a waiver of intellectual property protections on COVID vaccines. But over-reacting may only make matters worse.